Maksyutov R A, Yakubitskiy S N, Kolosova I V, Tregubchak T V, Shvalov A N, Gavrilova E V, Shchelkunov S N
State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, Russia.
Vavilovskii Zhurnal Genet Selektsii. 2022 Jul;26(4):394-401. doi: 10.18699/VJGB-22-48.
Due to cessation of mass smallpox vaccination in 1980, the collective immunity of humans against orthopoxvirus infections has virtually been lost. Therefore, the risk of spreading zoonotic human orthopoxvirus infections caused by monkeypox and cowpox viruses has increased in the world. First-generation smallpox vaccines based on Vaccinia virus (VAC) are reactogenic and therefore not suitable for mass vaccination under current conditions. This necessitates the development of modern safe live vaccines based on VAC using genetic engineering. We created the VACΔ6 strain by transient dominant selection. In the VACΔ6 genome, f ive virulence genes were intentionally deleted, and one gene was inactivated by inserting a synthetic DNA fragment. The virus was passaged 71 times in CV-1 cells to obtain the VACΔ6 strain from the VAC LIVP clonal variant. Such a long passage history might have led to additional off-target mutations in VACΔ6 compared to the original LIVP variant. To prevent this, we performed a genome-wide sequencing of VAC LIVP, VACΔ6, and f ive intermediate viral strains to assess possible off-target mutations. A comparative analysis of complete viral genomes showed that, in addition to target mutations, only two nucleotide substitutions occurred spontaneously when obtaining VACΔ4 from the VACΔ3 strain; the mutations persisting in the VACΔ5 and VACΔ6 genomes. Both nucleotide substitutions are located in intergenic regions (positions 1431 and 189738 relative to LIVP), which indicates an extremely rare occurrence of off-target mutations when using transient dominant selection to obtain recombinant VAC variants with multiple insertions/deletions. To assess the genome stability of the resulting attenuated vaccine strain, 15 consecutive cycles of cultivation of the industrial VACΔ6 strain were performed in 4647 cells certif ied for vaccine production in accordance with the "Guidelines for Clinical Trials of Medicinal Products". PCR and sequencing analysis of six DNA fragments corresponding to the regions of disrupted genes in VACΔ6 showed that all viral DNA sequences remained unchanged after 15 passages in 4647 cells.
由于1980年停止了大规模天花疫苗接种,人类对正痘病毒感染的群体免疫力实际上已经丧失。因此,由猴痘病毒和牛痘病毒引起的人畜共患人类正痘病毒感染在世界范围内传播的风险增加。基于痘苗病毒(VAC)的第一代天花疫苗具有反应原性,因此不适合在当前条件下进行大规模接种。这就需要利用基因工程开发基于VAC的现代安全活疫苗。我们通过瞬时显性选择创建了VACΔ6株。在VACΔ6基因组中,有意删除了五个毒力基因,并通过插入一个合成DNA片段使一个基因失活。该病毒在CV-1细胞中传代71次,从VAC LIVP克隆变体中获得VACΔ6株。与原始的LIVP变体相比,如此长的传代历史可能导致VACΔ6中出现额外的脱靶突变。为防止这种情况,我们对VAC LIVP、VACΔ6和五个中间病毒株进行了全基因组测序,以评估可能的脱靶突变。对完整病毒基因组的比较分析表明,除了目标突变外,从VACΔ3株获得VACΔ4时仅自发发生了两个核苷酸替换;这些突变在VACΔ5和VACΔ6基因组中持续存在。两个核苷酸替换均位于基因间区域(相对于LIVP的位置1431和189738),这表明在使用瞬时显性选择获得具有多个插入/缺失的重组VAC变体时,脱靶突变极其罕见。为评估所得减毒疫苗株的基因组稳定性,根据“药品临床试验指南”,在经认证可用于疫苗生产的4647细胞中对工业VACΔ6株进行了15个连续培养周期。对与VACΔ6中被破坏基因区域相对应的六个DNA片段进行PCR和测序分析表明,在4647细胞中传代15次后,所有病毒DNA序列均保持不变。